STOCK TITAN

Kaman Reports 2021 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Kaman Corp. (NYSE: KAMN) reported its financial results for Q4 and full year 2021. Net sales for 2021 reached $709 million with a gross margin of 33.4%. Earnings from continuing operations totaled $43.7 million, leading to diluted EPS of $1.57. For Q4, net sales were $175.1 million and earnings were $9.2 million. The company's cash flow from operations was $48.7 million for the year. Kaman anticipates improvement in product demand as markets recover from the pandemic, with effective management strategies yielding positive cash flow.

Positive
  • Net sales for 2021 were $709 million, demonstrating resilience.
  • Gross margin increased by more than 200 basis points to 33.4%.
  • Earnings from continuing operations improved to $43.7 million compared to a loss in 2020.
  • Adjusted EBITDA for the year was $95.5 million, maintaining a margin of 13.5%.
  • Strong cash flow from operations of $48.7 million supports future growth.
Negative
  • Q4 2021 net sales declined compared to both the previous quarter and the same quarter in 2020.
  • Earnings from continuing operations decreased significantly in Q4 compared to Q3 2021.
  • Precision Products segment faced revenue declines, particularly affecting JPF sales.
  • Overall adjusted EBITDA decreased in the Precision Products segment, indicating operational challenges.

Full Year 2021 Highlights:

  • Achieved our earnings targets by leveraging our new operations excellence model
  • Net sales: $709 million
  • Gross margin: 33.4%
  • Earnings from continuing operations: $43.7 million
  • Adjusted EBITDA*: $95.5 million; Adjusted EBITDA margin*: 13.5%
  • Diluted earnings per share from continuing operations: $1.57 per share, $1.93 per share adjusted*
  • Cash flow from operating activities: $48.7 million
  • Adjusted free cash flow*: $56.3 million

Fourth Quarter 2021 Highlights:

  • Net sales: $175.1 million
  • Earnings from continuing operations: $9.2 million
  • Adjusted EBITDA: $23.6 million; Adjusted EBITDA margin: 13.5%
  • Diluted earnings per share from continuing operations: $0.33 per share, $0.48 per share adjusted
  • Cash flow from operating activities: $34.6 million
  • Adjusted free cash flow of $28.4 million

BLOOMFIELD, Conn.--(BUSINESS WIRE)-- Kaman Corp. (NYSE:KAMN) today reported financial results for the fourth fiscal quarter and full year ended December 31, 2021

Table 1. Summary of Financial Results (unaudited)

Thousands of U.S. dollars

(except share data)

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,
2021

 

October 1,
2021

 

December 31,
2020

 

December 31,
2021

 

December 31,
2020

Net sales

 

$

175,147

 

 

$

179,836

 

 

$

185,288

 

 

$

708,993

 

 

$

784,459

 

Earnings (loss) from continuing operations

 

 

9,169

 

 

 

14,667

 

 

 

(31,420

)

 

 

43,676

 

 

 

(70,434

)

Adjusted EBITDA*

 

 

23,591

 

 

 

27,816

 

 

 

17,266

 

 

 

95,464

 

 

 

102,932

 

Adjusted EBITDA margin*

 

 

13.5

%

 

 

15.5

%

 

 

9.3

%

 

 

13.5

%

 

 

13.1

%

Diluted earnings (loss) per share from continuing operations

 

$

0.33

 

 

$

0.53

 

 

$

(1.13

)

 

$

1.57

 

 

$

(2.54

)

Adjusted diluted earnings per share from continuing operations*

 

 

0.48

 

 

 

0.60

 

 

 

0.41

 

 

 

1.93

 

 

 

2.11

 

*See the end of this release for an explanation of the Company's use of Adjusted EBITDA, Adjusted EBITDA margin, Adjusted free cash flow and Adjusted diluted earnings per share from continuing operations. See tables 6-12 for reconciliations to the most comparable GAAP measure.

"Kaman made significant progress in 2021 through the deployment of our new operations excellence model, which provides a sustainable foundation to achieve our financial targets. For the year, we achieved the targets for our adjusted metrics of EBITDA, EBITDA margin and earnings per share and delivered significantly more free cash flow. Gross margin increased more than 200 basis points to 33.4% driven by improved performance in several of our businesses, primarily in our seals, springs and contacts products. Additionally, our focus on reducing costs is providing long term benefits as evidenced by a decline in SG&A expenses," said Ian K. Walsh, Chairman, President and Chief Executive Officer.

"Beginning this quarter, we reported our results under a new segment structure. This reinforces Kaman's commitment to provide transparency of performance in support of our growth strategy and portfolio management. The three segments are Engineered Products, Precision Products and Structures. The new reporting segments align well with our product capabilities and our recently launched brand structure."

"During the fourth quarter we saw sequential improvement in sales to Boeing and Airbus, making it the second straight quarter of increased volumes. While we saw improved sales in the commercial, business and general aviation markets, results for the company declined, impacted by lower JPF sales in our Precision Products segment and lower demand for medical and industrial products in our Engineered Products segment. Demand in the medical and industrial markets declined slightly compared to the third quarter 2021, however, they remain elevated compared to 2020. Additionally, we continued to see strong cash generation in the fourth quarter leading to an Adjusted free cash flow of $28.4 million."

"We are committed to growing our business through innovation and have reached a number of milestones in 2021. In the first quarter, we began production of highly engineered products utilizing our proprietary Titanium Diffusion Hardening process. In the third quarter we unveiled our KARGO UAV unmanned aerial system, a purpose built autonomous medium lift logistics vehicle. In October 2021, we successfully completed the demonstration of two flight tests of FireBurstTM enhanced fuzing capability, a Kaman patented height of burst solution. These accomplishments support our strategic priority of achieving top quartile performance in the markets we serve," said Walsh.

Outlook

"Demand for Kaman's products should improve as end markets recover from the impact of the pandemic. The progress for Kaman will follow the acceleration of orders in the commercial, business and general aviation markets. In the latter part of 2022, we expect to see growth in our Engineered Products segment combined with improvement in our Structures segment resulting from our operations excellence efforts and a focus on adding new more profitable businesses. In our Precision Products segment, we will continue to manage prospective JPF direct commercial sales orders, which can be difficult to predict. For 2022 we expect the improvements in our other segments to mostly offset the decreased volumes for this program.

"We continue to see meaningful order increases across the commercial aerospace, defense as well as medical and industrial end markets, led by especially strong order intake for our bearings, springs, seals and contacts products. In addition, we entered into a follow-on multi-year contract with Sikorsky in December 2021 to continue the manufacture of the UH-60 Black Hawk cockpits. The strength in order activity gives us confidence that the backlog level we saw at the end of 2021 can be maintained, " Walsh said.

See Table 5 of this release for a full outlook summary for 2022.

KAMAN BUSINESS RESULTS DISCUSSION BY REPORTING SEGMENT

Kaman manages its portfolio through three segments: (1) Engineered Products; (2) Precision Products; and (3) Structures.

Engineered Products - Our Engineered Products segment serves the aerospace and defense, industrial and medical markets providing sophisticated, proprietary aircraft bearings and components; super precision, miniature ball bearings; and proprietary spring energized seals, springs and contacts.

Table 2. Engineered Products Results

 

 

 

 

 

 

Thousands of U.S. dollars

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,
2021

 

October 1,
2021

 

December 31,
2020

 

December 31,
2021

 

December 31,
2020

Net sales

 

$

82,549

 

 

$

84,399

 

 

$

79,929

 

 

$

317,683

 

 

$

315,063

 

Operating income

 

 

12,784

 

 

 

15,563

 

 

 

8,735

 

 

 

43,097

 

 

 

33,561

 

Adjusted EBITDA

 

 

19,364

 

 

 

22,120

 

 

 

17,212

 

 

 

69,403

 

 

 

65,367

 

Adjusted EBITDA margin

 

 

23.5

%

 

 

26.2

%

 

 

21.5

%

 

 

21.8

%

 

 

20.7

%

Three months ended December 31, 2021 versus three months ended October 1, 2021 - Adjusted EBITDA decreased $2.8 million and margin decreased 2.7 percentage points versus the third quarter of 2021. Compared to the prior period, volume declined modestly for products serving the medical end market.

Three months ended December 31, 2021 versus three months ended December 31, 2020 - Adjusted EBITDA increased $2.2 million and margin increased 2.0 percentage points versus the fourth quarter of 2020. Results improved compared to the prior period driven by higher sales and gross margin for products serving the medical end market and lower salary and wage expense at certain foreign locations partially offset by lower gross profit on our defense bearings.

Full year ended December 31, 2021 versus full year ended December 31, 2020 - Adjusted EBITDA increased $4.0 million and margin increased 1.1 percentage points versus 2020. Compared to the prior period, sales and gross profit increased on seals, springs and contacts for medical implantables, medical devices and analytical instruments. This was partially offset by lower sales volume of commercial bearing products driven by impacts of COVID-19 on the commercial aerospace end market.

Precision Products - Our Precision Products segment serves the aerospace and defense markets providing precision safe and arming solutions for missile and bomb systems for the U.S. and allied militaries; subcontract helicopter work; restoration, modification and support of our SH-2G Super Seasprite maritime helicopters; manufacture and support of our heavy lift K-MAX® manned helicopter, the K-MAX TITAN unmanned aerial system and the KARGO UAV unmanned aerial system, a purpose built autonomous medium lift logistics vehicle.

Table 3. Precision Products Results

 

 

 

 

 

 

Thousands of U.S. dollars

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,
2021

 

October 1,
2021

 

December 31,
2020

 

December 31,
2021

 

December 31,
2020

Net sales

 

$

60,673

 

 

$

63,584

 

 

$

69,532

 

 

$

256,329

 

 

$

302,509

 

Operating income

 

 

8,662

 

 

 

14,283

 

 

 

14,221

 

 

 

55,366

 

 

 

74,033

 

Adjusted EBITDA

 

 

9,703

 

 

 

15,305

 

 

 

15,289

 

 

 

59,514

 

 

 

77,739

 

Adjusted EBITDA margin

 

 

16.0

%

 

 

24.1

%

 

 

22.0

%

 

 

23.2

%

 

 

25.7

%

Three months ended December 31, 2021 versus three months ended October 1, 2021 - Adjusted EBITDA decreased $5.6 million and margin decreased 8.1 percentage points versus the third quarter of 2021. Results declined compared to the prior period primarily due to lower gross profit associated with the K-MAX® program and higher R&D spend associated with new technologies, such as KARGO UAV unmanned aerial system.

Three months ended December 31, 2021 versus three months ended December 31, 2020 - Adjusted EBITDA decreased $5.6 million and margin decreased 6.0 percentage points versus the fourth quarter of 2020. Results declined compared to the prior period, driven by lower margin on K-MAX® aircraft sales and higher R&D spend primarily on KARGO UAV unmanned aerial system.

Full year ended December 31, 2021 versus full year ended December 31, 2020 - Adjusted EBITDA decreased $18.2 million and margin decreased 2.5 percentage points versus 2020. Compared to the prior period, JPF DCS sales and associated gross profit decreased and gross profit on legacy fuzing programs declined. This was partially offset by higher sales and gross profit on the JPF USG program and higher sales volume and gross profit on the SH-2G program with New Zealand.

Structures - Our Structures segment serves the aerospace and defense and medical end markets providing sophisticated complex metallic and composite aerostructures for commercial, military and general aviation fixed and rotary wing aircraft, and medical imaging solutions.

Table 4. Structures Results

 

 

 

 

 

 

Thousands of U.S. dollars

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31,
2021

 

October 1,
2021

 

December 31,
2020

 

December 31,
2021

 

December 31,
2020

Net sales

 

$

31,925

 

 

$

31,853

 

 

$

35,827

 

 

$

134,981

 

 

$

166,887

 

Operating income (loss)

 

 

275

 

 

 

556

 

 

 

(6,534

)

 

 

(340

)

 

 

(8,858

)

Adjusted EBITDA

 

 

1,164

 

 

 

1,413

 

 

 

(5,307

)

 

 

3,122

 

 

 

(3,657

)

Adjusted EBITDA margin

 

 

3.6

%

 

 

4.4

%

 

 

(14.8

)%

 

 

2.3

%

 

 

(2.2

)%

Three months ended December 31, 2021 versus three months ended October 1, 2021 - Adjusted EBITDA and margin were relatively unchanged compared to the third quarter of 2021. Results were impacted by lower gross profit due to changes in profit estimates for long term contracts offset by higher sales volumes on our AH-1Z program.

Three months ended December 31, 2021 versus three months ended December 31, 2020 - Adjusted EBITDA increased $6.5 million and margin increased 18.4 percentage points versus the fourth quarter of 2020. Compared to the prior period, results improved driven by the absence of losses from the former UK composites business and higher gross profit on certain metallic structure programs due to our continuous improvement efforts.

Full year ended December 31, 2021 versus full year ended December 31, 2020 - Adjusted EBITDA increased $6.8 million and margin increased 4.5 percentage points versus 2020. Compared to the prior period, results increased driven by the absence of losses from the former UK Composites business and higher sales and gross profit on the A-10 program. This was partially offset by lower gross profit on the Boeing Wing-to-Body Fairing program.

Please see the MD&A section of the Company's Form 10-K filed with the Securities and Exchange Commission concurrently with the issuance of this release for greater detail on our results and various company programs.

OUTLOOK

Table 5. Outlook

Millions of U.S. dollars (except share data)

 

 

2021

 

 

2022 Outlook

 

 

Actual

 

Low End

 

High End

Net Sales

 

$

709.0

 

 

$

720.0

 

 

$

740.0

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

 

 

 

 

 

Earnings from continuing operations

 

$

43.7

 

 

$

49.3

 

 

$

53.5

 

Interest expense, net

 

 

16.3

 

 

 

15.7

 

 

 

15.7

 

Income tax expense

 

 

16.8

 

 

 

13.1

 

 

 

14.2

 

Non-service pension and post retirement benefit income

 

 

(26.2

)

 

 

(21.1

)

 

 

(21.1

)

Other income, net

 

 

(0.1

)

 

 

(0.9

)

 

 

(0.9

)

Income from TSA

 

 

(0.9

)

 

 

 

 

 

 

Depreciation and amortization

 

 

36.6

 

 

 

37.6

 

 

 

37.6

 

Other adjustments

 

 

9.3

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

95.5

 

 

$

93.7

 

 

$

99.0

 

Adjusted EBITDA margin

 

 

13.5

%

 

 

13.0

%

 

 

13.4

%

 

 

 

 

 

 

 

Adjusted Diluted Earnings Per Share

 

 

 

 

 

 

Diluted earnings per share

 

$

1.57

 

 

$

1.75

 

 

$

1.90

 

Adjustments

 

 

0.36

 

 

 

 

 

 

 

Adjusted diluted earnings per share

 

$

1.93

 

 

$

1.75

 

 

$

1.90

 

 

 

 

 

 

 

 

Cash Flow

 

 

 

 

 

 

Cash flow from operating activities(1)

 

$

48.7

 

 

$

65.0

 

 

$

75.0

 

Bal Seal Acquisition Retention Payment

 

 

25.1

 

 

 

 

 

 

 

Expenditures for property, plant and equipment

 

 

(17.5

)

 

 

(25.0

)

 

 

(25.0

)

Adjusted free cash flow

 

$

56.3

 

 

$

40.0

 

 

$

50.0

 

 

 

 

 

 

 

 

Discretionary Pension Contribution

 

$

10.0

 

 

$

 

 

$

 

(1) Cash flow from operating activities in 2021 includes the $25.1 million payment to Bal Seal employees which represents purchase price paid to the former Bal Seal owners that was accounted for as compensation expense under ASC 805 in 2020.

CONFERENCE CALL

A conference call has been scheduled for tomorrow, February 25, 2022, at 8:30 AM ET. The call will be accessible by telephone within the U.S. at (844) 473-0975 and from outside the U.S. at (562) 350-0826 (using the Conference I.D.: 3966827) or via the Internet at www.kaman.com. A replay will be available two hours after the call and can be accessed at (855) 859-2056 or (404) 537-3406 using the Conference I.D.: 3966827. In its discussion, management may reference certain non-GAAP financial measures related to company performance. A reconciliation of that information to the most directly comparable GAAP measures is provided in this release. In addition, a supplemental presentation relating to the fourth quarter 2021 results will be posted to the Company’s website prior to the earnings call at www.kaman.com/investors/investor-presentations.

ABOUT KAMAN CORPORATION

Kaman Corporation, founded in 1945 by aviation pioneer Charles H. Kaman, and headquartered in Bloomfield, Connecticut, conducts business in the aerospace & defense, industrial and medical markets. Kaman produces and markets proprietary aircraft bearings and components; super precision, miniature ball bearings; proprietary spring energized seals, springs and contacts; complex metallic and composite aerostructures for commercial, military and general aviation fixed and rotary wing aircraft; safe and arming solutions for missile and bomb systems for the U.S. and allied militaries; subcontract helicopter work; restoration, modification and support of our SH-2G Super Seasprite maritime helicopters; manufacture and support of our heavy lift K-MAX® manned helicopter, the K-MAX TITAN unmanned helicopter and the KARGO UAV unmanned aerial system, a purpose built autonomous medium lift logistics vehicle. More information is available at www.kaman.com.

NON-GAAP MEASURES DISCLOSURE

Management believes that the Non-GAAP financial measures (i.e. financial measures that are not computed in accordance with Generally Accepted Accounting Principles) identified by an asterisk (*) used in this release or in other disclosures provide important perspectives into the Company's ongoing business performance. The Company does not intend for the information to be considered in isolation or as a substitute for the related GAAP measures. Other companies may define the measures differently. We define the Non-GAAP measures used in this release and other disclosures as follows:

Adjusted EBITDA - Adjusted EBITDA is defined as earnings from continuing operations before interest, taxes, other expense (income), net, depreciation and amortization and certain items that are not indicative of the operating performance of the Company for the periods presented. Adjusted EBITDA differs from earnings from continuing operations, as calculated in accordance with GAAP, in that it excludes interest expense, net, income tax expense, depreciation and amortization, other expense (income), net, non-service pension and post retirement benefit expense (income), and certain items that are not indicative of the operating performance of the Company for the periods presented. We have made numerous investments in our business, such as acquisitions and capital expenditures, including facility improvements, new machinery and equipment, improvements to our information technology infrastructure and ERP systems, which we have adjusted for in Adjusted EBITDA. Adjusted EBITDA also does not give effect to cash used for debt service requirements and thus does not reflect funds available for distributions, reinvestments or other discretionary uses. Management believes Adjusted EBITDA provides an additional perspective on the operating results of the organization and its earnings capacity and helps improve the comparability of our results between periods because it provides a view of our operations that excludes items that management believes are not reflective of operating performance, such as items traditionally removed from net earnings in the calculation of EBITDA as well as Other expense (income), net and certain items that are not indicative of the operating performance of the Company for the period presented. Adjusted EBITDA is not presented as an alternative measure of operating performance, as determined in accordance with GAAP. No other adjustments were made during the three-month fiscal periods ended December 31, 2021, October 1, 2021 and December 31, 2020 and twelve-month fiscal periods ended December 31, 2021 and December 31, 2020. The following tables illustrate the calculation of Adjusted EBITDA:

Table 6. Adjusted EBITDA (unaudited)

 

 

 

 

Thousands of U.S. dollars

 

Three Months Ended
December 31, 2021

 

 

Consolidated

 

Engineered
Products

 

Precision
Products

 

Structures

 

Corp/Elims**

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

Consolidated Results

 

 

 

 

 

 

 

 

 

 

Sales from continuing operations

 

$

175,147

 

 

$

82,549

 

 

$

60,673

 

 

$

31,925

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) from continuing operations, net of tax

 

$

9,169

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

4,058

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

6,676

 

 

 

 

 

 

 

 

 

Non-service pension and post retirement benefit income

 

 

(6,397

)

 

 

 

 

 

 

 

 

Other income, net

 

 

(417

)

 

 

 

 

 

 

 

 

Operating income (loss)

 

$

13,089

 

 

$

12,784

 

 

$

8,662

 

 

$

275

 

 

$

(8,632

)

Depreciation and amortization

 

 

9,180

 

 

 

6,580

 

 

 

1,041

 

 

 

889

 

 

 

670

 

Restructuring and severance costs

 

 

675

 

 

 

 

 

 

 

 

 

 

 

 

675

 

Cost associated with corporate development activities

 

 

647

 

 

 

 

 

 

 

 

 

 

 

 

647

 

Other Adjustments

 

$

10,502

 

 

$

6,580

 

 

$

1,041

 

 

$

889

 

 

$

1,992

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

23,591

 

 

$

19,364

 

 

$

9,703

 

 

$

1,164

 

 

$

(6,640

)

Adjusted EBITDA margin

 

 

13.5

%

 

 

23.5

%

 

 

16.0

%

 

 

3.6

%

 

 

**Corp/Elims Operating income (loss) represents the Corporate office expenses and $0.7 million of unallocated expenses that are shown on the Consolidated Statement of Earnings as their own line items.

Table 7. Adjusted EBITDA (unaudited)

 

 

 

 

Thousands of U.S. dollars

 

Three Months Ended
October 1, 2021

 

 

Consolidated

 

Engineered
Products

 

Precision
Products

 

Structures

 

Corp/Elims**

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

Consolidated Results

 

 

 

 

 

 

 

 

 

 

Sales from continuing operations

 

$

179,836

 

 

$

84,399

 

 

$

63,584

 

 

$

31,853

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) from continuing operations, net of tax

 

$

14,667

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

3,646

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

4,447

 

 

 

 

 

 

 

 

 

Non-service pension and post retirement benefit income

 

 

(6,612

)

 

 

 

 

 

 

 

 

Other income, net

 

 

(172

)

 

 

 

 

 

 

 

 

Income from TSA

 

 

(14

)

 

 

 

 

 

 

 

 

Operating income (loss)

 

$

15,962

 

 

$

15,563

 

 

$

14,283

 

 

$

556

 

 

$

(14,440

)

Depreciation and amortization

 

 

9,083

 

 

 

6,557

 

 

 

1,022

 

 

 

857

 

 

 

647

 

Restructuring and severance costs

 

 

2,611

 

 

 

 

 

 

 

 

 

 

 

 

2,611

 

Cost associated with corporate development activities

 

 

136

 

 

 

 

 

 

 

 

 

 

 

 

136

 

Costs from transition service agreement

 

 

24

 

 

 

 

 

 

 

 

 

 

 

 

24

 

Other Adjustments

 

$

11,854

 

 

$

6,557

 

 

$

1,022

 

 

$

857

 

 

$

3,418

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

27,816

 

 

$

22,120

 

 

$

15,305

 

 

$

1,413

 

 

$

(11,022

)

Adjusted EBITDA margin

 

 

15.5

%

 

 

26.2

%

 

 

24.1

%

 

 

4.4

%

 

 

**Corp/Elims Operating income (loss) represents the Corporate office expenses and $2.6 million of unallocated expenses that are shown on the Consolidated Statement of Earnings as their own line items.

Table 8. Adjusted EBITDA (unaudited)

 

 

 

 

Thousands of U.S. dollars

 

Three Months Ended
December 31, 2020

 

 

Consolidated

 

Engineered
Products

 

Precision
Products

 

Structures

 

Corp/Elims**

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

Consolidated Results

 

 

 

 

 

 

 

 

 

 

Sales from continuing operations

 

$

185,288

 

 

$

79,929

 

 

$

69,532

 

 

$

35,827

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) from continuing operations, net of tax

 

$

(31,420

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

4,888

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

(6,708

)

 

 

 

 

 

 

 

 

Non-service pension and post retirement benefit income

 

 

(4,062

)

 

 

 

 

 

 

 

 

Other income, net

 

 

(304

)

 

 

 

 

 

 

 

 

Income from TSA

 

 

(586

)

 

 

 

 

 

 

 

 

Operating income (loss)

 

$

(38,192

)

 

$

8,735

 

 

$

14,221

 

 

$

(6,534

)

 

$

(54,614

)

Depreciation and amortization

 

 

11,695

 

 

 

8,477

 

 

 

1,068

 

 

 

1,227

 

 

 

923

 

Impairment on assets held for sale

 

 

36,285

 

 

 

 

 

 

 

 

 

 

 

 

36,285

 

Restructuring and severance costs

 

 

539

 

 

 

 

 

 

 

 

 

 

539

 

Cost associated with corporate development activities

 

 

207

 

 

 

 

 

 

 

 

 

 

 

 

207

 

Bal Seal acquisition costs

 

 

45

 

 

 

 

 

 

 

 

 

 

 

 

45

 

Cost of acquired Bal Seal retention plans

 

 

5,704

 

 

 

 

 

 

 

 

 

 

 

 

5,704

 

Costs from transition services agreement

 

 

983

 

 

 

 

 

 

 

 

 

 

 

 

983

 

Other Adjustments

 

$

55,458

 

 

$

8,477

 

 

$

1,068

 

 

$

1,227

 

 

$

44,686

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

17,266

 

 

$

17,212

 

 

$

15,289

 

 

$

(5,307

)

 

$

(9,928

)

Adjusted EBITDA margin

 

 

9.3

%

 

 

21.5

%

 

 

22.0

%

 

 

(14.8

)%

 

 

**Corp/Elims Operating income (loss) represents the Corporate office expenses and $43.7 million of unallocated expenses that are shown on the Consolidated Statement of Earnings as their own line items.

Table 9. Adjusted EBITDA (unaudited)

 

 

 

 

Thousands of U.S. dollars

 

Twelve Months Ended
December 31, 2021

 

 

Consolidated

 

Engineered
Products

 

Precision
Products

 

Structures

 

Corp/Elims**

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

Consolidated Results

 

 

 

 

 

 

 

 

 

 

Sales from continuing operations

 

$

708,993

 

 

$

317,683

 

 

$

256,329

 

 

$

134,981

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) from continuing operations, net of tax

 

 

43,676

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

16,290

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

16,832

 

 

 

 

 

 

 

 

 

Non-service pension and post retirement benefit income

 

 

(26,229

)

 

 

 

 

 

 

 

 

Other income, net

 

 

(142

)

 

 

 

 

 

 

 

 

Income from TSA

 

 

(931

)

 

 

 

 

 

 

 

 

Operating income (loss)

 

$

49,496

 

 

$

43,097

 

 

$

55,366

 

 

$

(340

)

 

$

(48,627

)

Depreciation and amortization

 

 

36,654

 

 

 

26,306

 

 

 

4,148

 

 

 

3,462

 

 

 

2,738

 

Restructuring and severance costs

6,154

6,154

 

Cost associated with corporate development activities

 

 

1,198

 

 

 

 

 

 

 

 

 

 

 

 

1,198

 

Costs from transition services agreement

 

 

1,728

 

 

 

 

 

 

 

 

 

 

 

 

1,728

 

Loss on sale of business

 

 

234

 

 

 

 

 

 

 

 

 

 

 

 

234

 

Other Adjustments

 

$

45,968

 

 

$

26,306

 

 

$

4,148

 

 

$

3,462

 

 

$

12,052

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

95,464

 

 

$

69,403

 

 

$

59,514

 

 

$

3,122

 

 

$

(36,575

)

Adjusted EBITDA margin

 

 

13.5

%

 

 

21.8

%

 

 

23.2

%

 

 

2.3

%

 

 

**Corp/Elims Operating income (loss) represents the Corporate office expenses and $8.1 million of unallocated expenses that are shown on the Consolidated Statement of Earnings as their own line items.

Table 10. Adjusted EBITDA (unaudited)

 

 

 

 

 

Thousands of U.S. dollars

 

Twelve Months Ended
December 31, 2020

 

 

Consolidated

 

Engineered
Products

 

Precision
Products

 

Structures

 

Corp/Elims*

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

Consolidated Results

 

 

 

 

 

 

 

 

 

 

 

Sales from continuing operations

 

$

784,459

 

 

$

315,063

 

 

$

302,509

 

 

$

166,887

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) from continuing operations, net of tax

 

$

(70,434

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

19,270

 

 

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

 

(7,730

)

 

 

 

 

 

 

 

 

 

Non-service pension and post retirement benefit income

 

 

(16,250

)

 

 

 

 

 

 

 

 

 

Other income, net

 

 

(728

)

 

 

 

 

 

 

 

 

 

Income from TSA

 

 

(8,439

)

 

 

 

 

 

 

 

 

 

Operating income (loss)

 

$

(84,311

)

 

$

33,561

 

 

$

74,033

 

 

$

(8,858

)

 

$

(183,047

)

Depreciation and amortization

 

 

43,899

 

 

 

31,574

 

 

 

3,706

 

 

 

5,201

 

 

 

3,418

 

Non-cash, non tax goodwill impairment charge

 

 

50,307

 

 

 

 

 

 

 

 

 

 

 

 

50,307

 

Impairment on assets held for sale

 

 

36,285

 

 

 

 

 

 

 

 

 

 

 

 

36,285

 

Restructuring and severance costs

 

 

8,359

 

 

 

 

 

 

 

 

 

 

 

 

8,359

 

Cost associated with corporate development activities

 

 

4,539

 

 

 

 

 

 

 

 

 

 

 

 

4,539

 

Bal Seal acquisition costs

 

 

8,506

 

 

 

 

 

 

 

 

 

 

 

 

8,506

 

Cost of acquired Bal Seal retention plans

 

 

22,814

 

 

 

 

 

 

 

 

 

 

 

 

22,814

 

Inventory step-up associated with Bal Seal acquisition

 

 

2,355

 

 

 

2,355

 

 

 

 

 

 

 

 

 

 

Costs from transition services agreement

 

 

12,515

 

 

 

 

 

 

 

 

 

 

 

 

12,515

 

Senior leadership transition

 

 

280

 

 

 

 

 

 

 

 

 

 

 

 

280

 

Reversal of employee tax-related matters in foreign operations

 

 

(1,859

)

 

 

(1,859

)

 

 

 

 

 

 

 

 

 

Reversal of environmental accrual at GRW

 

 

(264

)

 

 

(264

)

 

 

 

 

 

 

 

 

 

Gain on sale of business

 

 

(493

)

 

 

 

 

 

 

 

 

 

 

(493

)

Other Adjustments

 

$

187,243

 

 

$

31,806

 

 

$

3,706

 

 

$

5,201

 

 

$

146,530

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

102,932

 

 

$

65,367

 

 

$

77,739

 

 

$

(3,657

)

 

$

(36,517

)

Adjusted EBITDA margin

 

 

13.1

%

 

 

20.7

%

 

 

25.7

%

 

 

(2.2

)%

 

 

**Corp/Elims Operating income (Loss) represents the Corporate office expenses and $130.0 million of unallocated expenses that are shown on the Consolidated Statement of Earnings as their own line items.

Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings Per Share - Adjusted earnings from continuing operations and adjusted diluted earnings per share are defined as GAAP "Earnings from continuing operations" and "Diluted earnings per share from continuing operations", less items that are not indicative of the operating performance of the business for the periods presented. These items are included in the reconciliation below. Management uses adjusted earnings from continuing operations and adjusted diluted earnings per share to evaluate performance period over period, to analyze the underlying trends in our business and to assess its performance relative to its competitors. We believe that this information is useful for investors and financial institutions seeking to analyze and compare companies on the basis of operating performance.

The following table illustrates the calculation of adjusted earnings from continuing operations and adjusted diluted earnings per share:

Table 11. Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share (unaudited)

Thousands of U.S. dollars (except share data)

 

 

 

 

 

 

 

 

Three Months Ended

 

Three Months Ended

 

 

December 31, 2021

 

December 31, 2020

 

 

Pre-Tax

 

Tax-Effected

 

Diluted EPS

 

Pre-Tax

 

Tax-Effected

 

Diluted EPS

Earnings (loss) from continuing operations

 

$

15,845

 

 

$

9,169

 

 

$

0.33

 

 

$

(38,128

)

 

$

(31,420

)

 

$

(1.13

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Impairments on assets held for sale

 

 

 

 

 

 

 

 

 

 

 

36,285

 

 

 

36,285

 

 

 

1.31

 

Restructuring and severance costs

 

 

675

 

 

 

530

 

 

 

0.02

 

 

 

539

 

 

 

416

 

 

 

0.01

 

Costs associated with corporate development activities

 

 

647

 

 

 

508

 

 

 

0.02

 

 

 

207

 

 

 

160

 

 

 

0.01

 

Bal Seal acquisition costs

 

 

 

 

 

 

 

 

 

 

 

45

 

 

 

35

 

 

 

 

Cost of acquired Bal Seal retention plans

 

 

 

 

 

 

 

 

 

 

 

5,704

 

 

 

5,704

 

 

 

0.21

 

Costs from transition services agreement

 

 

 

 

 

 

 

 

 

 

 

983

 

 

 

758

 

 

 

0.02

 

Income from transition services agreement

 

 

 

 

 

 

 

 

 

 

 

(586

)

 

 

(452

)

 

 

(0.02

)

Tax-related items

 

 

3,131

 

 

 

3,131

 

 

 

0.11

 

 

 

 

 

 

 

 

 

 

Adjustments

 

$

4,453

 

 

$

4,169

 

 

$

0.15

 

 

$

43,177

 

 

$

42,906

 

 

$

1.54

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings from continuing operations

 

$

20,298

 

 

$

13,338

 

 

$

0.48

 

 

$

5,049

 

 

$

11,486

 

 

$

0.41

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted average shares outstanding

 

 

 

 

 

 

27,898

 

 

 

 

 

 

 

27,735

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

October 1, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pre-Tax

 

Tax-Effected

 

Diluted EPS

Earnings (loss) from continuing operations

 

$

19,114

 

 

$

14,667

 

 

$

0.53

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring and severance costs

 

 

2,611

 

 

 

2,003

 

 

 

0.07

 

Costs associated with corporate development activities

 

 

136

 

 

 

104

 

 

 

 

Costs from transition services agreement

 

 

24

 

 

 

18

 

 

 

 

Income from transition services agreement

 

 

(14

)

 

 

(11

)

 

 

 

Adjustments

 

$

2,757

 

 

$

2,114

 

 

$

0.07

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings from continuing operations

 

$

21,871

 

 

$

16,781

 

 

$

0.60

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted average shares outstanding

 

 

 

 

 

 

27,888

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Table 11 (cont). Adjusted Earnings from Continuing Operations and Adjusted Diluted Earnings per Share (unaudited)

Thousands of U.S. dollars (except share data)

 

 

 

 

 

 

 

 

Twelve Months Ended

 

Twelve Months Ended

 

 

December 31, 2021

 

December 31, 2020

 

 

Pre-Tax

 

Tax-Effected

 

Diluted EPS

 

Pre-Tax

 

Tax-Effected

 

Diluted EPS

Earnings (loss) from continuing operations

 

$

60,508

 

 

$

43,676

 

 

$

1.57

 

 

 

(78,164

)

 

$

(70,434

)

 

$

(2.54

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Noncash, non tax goodwill impairment charge

 

 

 

 

 

 

 

 

 

 

 

50,307

 

 

 

50,307

 

 

 

1.82

 

Impairment on assets held for sale

 

 

 

 

 

 

 

 

 

 

 

36,285

 

 

 

36,285

 

 

 

1.31

 

Restructuring and severance costs

 

 

6,154

 

 

 

4,810

 

 

 

0.17

 

 

 

8,359

 

 

 

6,448

 

 

 

0.23

 

Costs associated with corporate development activities

 

 

1,198

 

 

 

941

 

 

 

0.04

 

 

 

4,539

 

 

 

3,501

 

 

 

0.13

 

Bal Seal acquisition costs

 

 

 

 

 

 

 

 

 

 

8,506

 

 

 

6,602

 

 

 

0.24

 

Cost of acquired Bal Seal retention plans

 

 

 

 

 

 

 

 

 

 

 

22,814

 

 

 

22,814

 

 

 

0.82

 

Inventory step-up associated with Bal Seal acquisition

 

 

 

 

 

 

 

 

 

 

 

2,355

 

 

 

1,828

 

 

 

0.06

 

Costs from transition services agreement

 

 

1,728

 

 

 

1,370

 

 

 

0.05

 

 

 

12,515

 

 

 

9,654

 

 

 

0.34

 

Income from transition services agreement

 

 

(931

)

 

 

(739

)

 

 

(0.03

)

 

 

(8,439

)

 

 

(6,510

)

 

 

(0.23

)

Senior leadership transition

 

 

 

 

 

 

 

 

 

 

 

280

 

 

 

216

 

 

 

0.01

 

Employee tax-related matters in foreign operations

 

 

 

 

 

 

 

 

 

 

 

(1,859

)

 

 

(1,692

)

 

 

(0.06

)

Reversal of environmental accrual at GRW

 

 

 

 

 

 

 

 

 

 

 

(264

)

 

 

(187

)

 

 

(0.01

)

Loss (gain) on sale of business

 

 

234

 

 

 

234

 

 

 

0.01

 

 

 

(493

)

 

 

(370

)

 

 

(0.01

)

Tax-related items

 

 

3,131

 

 

 

3,131

 

 

 

0.11

 

 

 

 

 

 

 

 

 

 

Tax effect on sale of UK operations

 

 

287

 

 

 

287

 

 

 

0.01

 

 

 

 

 

 

 

 

 

 

Adjustments

 

$

11,801

 

 

$

10,034

 

 

$

0.36

 

 

$

134,905

 

 

$

128,896

 

 

$

4.65

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted earnings from continuing operations

 

$

72,309

 

 

$

53,710

 

 

$

1.93

 

 

$

56,741

 

 

$

58,462

 

 

$

2.11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted average shares outstanding

 

 

 

 

 

 

27,891

 

 

 

 

 

 

 

27,723

 

Adjusted Free Cash Flow - Adjusted free cash flow is defined as GAAP “Net cash provided by (used in) operating activities from continuing operations” in a period less “Expenditures for property, plant & equipment” in the same period and any adjustments that are representative of the Company's cash generation or usage in the period. For 2021 we adjusted free cash flow to remove the cash payment made to Bal Seal employees under the retention plan established by the former owners of Bal Seal. Management believes free cash flow from continuing operations and adjusted free cash flow provides an important perspective on our ability to generate cash from our business operations and, as such, that it is an important financial measure for use in evaluating the Company's financial performance. Free cash flow and adjusted free cash flow should not be viewed as representing the residual cash flow available for discretionary expenditures such as dividends to shareholders or acquisitions, as it may exclude certain mandatory expenditures such as repayment of maturing debt and other contractual obligations. Management uses free cash flow and Adjusted free cash flow internally to assess overall liquidity. The following table illustrates the calculation of adjusted free cash flow.

Table 12. Adjusted Free Cash Flow (unaudited)

Thousands of U.S. dollars

 

Twelve Months
Ended

 

Nine Months
Ended

 

Three Months
Ended

 

 

December 31,
2021

 

October 1,
2021

 

December 31,
2021

Net cash provided by operating activities from continuing operations

 

$

48,698

 

 

$

14,123

 

 

$

34,575

 

Expenditures for property, plant & equipment

 

 

(17,530

)

 

 

(11,364

)

 

 

(6,166

)

Cash paid for acquired retention plans (1)

 

 

25,108

 

 

 

25,108

 

 

 

 

Adjusted free cash flow

 

$

56,276

 

 

$

27,867

 

 

$

28,409

 

(1) Operating cash flow from continuing operations includes the $25.1 million payment to Bal Seal employees from the first quarter of 2021, which represents purchase price paid to the former Bal Seal owners accounted for as compensation under ASC 805.

FORWARD-LOOKING STATEMENTS

This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "would," "could," "will" and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others: (i) changes in domestic and foreign economic and competitive conditions in markets served by the Company, particularly the defense, commercial aviation and industrial production markets; (ii) changes in government and customer priorities and requirements (including cost-cutting initiatives, government and customer shut-downs, the potential deferral of awards, terminations or reductions of expenditures to respond to the priorities of Congress and the Administration, or budgetary cuts resulting from Congressional actions or automatic sequestration); (iii) the global economic impact of the COVID-19 pandemic; (iv) changes in geopolitical conditions in countries where the Company does or intends to do business; (v) the successful conclusion of competitions for government programs (including new, follow-on and successor programs) and thereafter successful contract negotiations with government authorities (both foreign and domestic) for the terms and conditions of the programs; (vi) the timely receipt of any necessary export approvals and/or other licenses or authorizations from the USG; (vii) timely satisfaction or fulfillment of material contractual conditions precedents in customer purchase orders, contracts, or similar arrangements; (viii) the existence of standard government contract provisions permitting renegotiation of terms and termination for the convenience of the government; (ix) the successful resolution of government inquiries or investigations relating to our businesses and programs; (x) risks and uncertainties associated with the successful implementation and ramp up of significant new programs, including the ability to manufacture the products to the detailed specifications required and recover start-up costs and other investments in the programs; (xi) potential difficulties associated with variable acceptance test results, given sensitive production materials and extreme test parameters; (xii) the receipt and successful execution of production orders under the Company's existing USG JPF contract, including the exercise of all contract options and receipt of orders from allied militaries, but excluding any next generation programmable fuze programs, as all have been assumed in connection with goodwill impairment evaluations; (xiii) the continued support of the existing K-MAX® helicopter fleet, including sale of existing K-MAX® spare parts inventory and the receipt of orders for new aircraft sufficient to recover our investments in the K-MAX® production line; (xiv) the accuracy of current cost estimates associated with environmental remediation activities; (xv) the profitable integration of acquired businesses into the Company's operations; (xvi) the ability to recover from cyber-based or other security attacks, information technology failures or other disruptions; (xvii) changes in supplier sales or vendor incentive policies; (xviii) the ability of our suppliers to satisfy their performance obligations, including any supply chain disruptions; (xix) the effects of price increases or decreases; (xx) the effects of pension regulations, pension plan assumptions, pension plan asset performance, future contributions and the pension freeze, including the ultimate determination of the USG's share of any pension curtailment adjustment calculated in accordance with CAS 413; (xxi) future levels of indebtedness and capital expenditures; (xxii) the continued availability of raw materials and other commodities in adequate supplies and the effect of increased costs for such items; (xxiii) the effects of currency exchange rates and foreign competition on future operations; (xxiv) changes in laws and regulations, taxes, interest rates, inflation rates and general business conditions; (xxv) future repurchases and/or issuances of common stock;(xxvi) the occurrence of unanticipated restructuring costs or the failure to realize anticipated savings or benefits from past or future expense reduction actions; (xxvii) the ability to recruit and retain skilled employees; and (xxviii) other risks and uncertainties set forth herein and in our 2021 Form 10-K.

Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

KAMAN CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Thousands of U.S. dollars, except share data) (unaudited)

 

 

 

Three Months Ended

 

Twelve Months Ended

 

 

December 31, 2021

 

December 31, 2020

 

December 31, 2021

 

December 31, 2020

Net sales

 

$

175,147

 

 

$

185,288

 

 

$

708,993

 

 

$

784,459

 

Cost of sales

 

 

116,445

 

 

 

130,951

 

 

 

472,375

 

 

 

538,877

 

Gross profit

 

 

58,702

 

 

 

54,337

 

 

 

236,618

 

 

 

245,582

 

Selling, general and administrative expenses

 

 

36,292

 

 

 

40,997

 

 

 

152,474

 

 

 

169,485

 

Goodwill impairment

 

 

 

 

 

 

 

 

 

 

 

50,307

 

Impairment on assets held for sale

 

 

 

 

 

36,285

 

 

 

 

 

 

36,285

 

Research and development costs

 

 

6,068

 

 

 

3,419

 

 

 

16,072

 

 

 

14,755

 

Intangible asset amortization expense

 

 

2,570

 

 

 

4,397

 

 

 

10,468

 

 

 

15,666

 

Costs from transition services agreement

 

 

 

 

 

983

 

 

 

1,728

 

 

 

12,515

 

Cost of acquired retention plans

 

 

 

 

 

5,704

 

 

 

 

 

 

22,814

 

Restructuring and severance costs

 

 

675

 

 

 

539

 

 

 

6,154

 

 

 

8,359

 

Loss (gain) on sale of business

 

 

 

 

 

 

 

 

234

 

 

 

(493

)

Net loss (gain) on sale of assets

 

 

8

 

 

 

205

 

 

 

(8

)

 

 

200

 

Operating income (loss)

 

 

13,089

 

 

 

(38,192

)

 

 

49,496

 

 

 

(84,311

)

Interest expense, net

 

 

4,058

 

 

 

4,888

 

 

 

16,290

 

 

 

19,270

 

Non-service pension and post retirement benefit income

 

 

(6,397

)

 

 

(4,062

)

 

 

(26,229

)

 

 

(16,250

)

Income from transition services agreement

 

 

 

 

 

(586

)

 

 

(931

)

 

 

(8,439

)

Other income, net

 

 

(417

)

 

 

(304

)

 

 

(142

)

 

 

(728

)

Earnings (loss) from continuing operations before income taxes

 

 

15,845

 

 

 

(38,128

)

 

 

60,508

 

 

 

(78,164

)

Income tax expense (benefit)

 

 

6,676

 

 

 

(6,708

)

 

 

16,832

 

 

 

(7,730

)

Earnings (loss) from continuing operations

 

 

9,169

 

 

 

(31,420

)

 

 

43,676

 

 

 

(70,434

)

Earnings from discontinued operations before gain on disposal, net of tax

 

 

 

 

 

 

 

 

 

 

 

 

Gain on disposal of discontinued operations, net of tax

 

 

 

 

 

 

 

 

 

 

 

692

 

Total earnings from discontinued operations

 

 

 

 

 

 

 

 

 

 

 

692

 

Net earnings (loss)

 

$

9,169

 

 

$

(31,420

)

 

$

43,676

 

 

$

(69,742

)

 

 

 

 

 

 

 

 

 

Earnings per share:

 

 

 

 

 

 

 

 

Basic earnings (loss) per share from continuing operations

 

$

0.33

 

 

$

(1.13

)

 

$

1.57

 

 

$

(2.54

)

Basic earnings per share from discontinued operations

 

 

0.00

 

 

 

0.00

 

 

 

0.00

 

 

 

0.02

 

Basic earnings (loss) per share

 

$

0.33

 

 

$

(1.13

)

 

$

1.57

 

 

$

(2.52

)

Diluted earnings (loss) per share from continuing operations

 

$

0.33

 

 

$

(1.13

)

 

$

1.57

 

 

$

(2.54

)

Diluted earnings per share from discontinued operations

 

 

0.00

 

 

 

0.00

 

 

 

0.00

 

 

 

0.02

 

Diluted earnings (loss) per share

 

$

0.33

 

 

$

(1.13

)

 

$

1.57

 

 

$

(2.52

)

Average shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

 

27,896

 

 

 

27,735

 

 

 

27,865

 

 

 

27,723

 

Diluted

 

 

27,898

 

 

 

27,735

 

 

 

27,891

 

 

 

27,723

 

KAMAN CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Thousands of U.S. dollars, except share data) (unaudited)

 

 

 

December 31, 2021

 

December 31, 2020

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

140,800

 

 

$

104,377

 

Restricted cash

 

 

 

 

 

25,121

 

Accounts receivable, net

 

 

73,524

 

 

 

153,806

 

Contract assets

 

 

112,354

 

 

 

108,645

 

Contract costs, current portion

 

 

850

 

 

 

3,511

 

Inventories

 

 

193,100

 

 

 

185,072

 

Income tax refunds receivable

 

 

13,832

 

 

 

5,269

 

Other current assets

 

 

12,083

 

 

 

12,173

 

Total current assets

 

 

546,543

 

 

 

597,974

 

Property, plant and equipment, net of accumulated depreciation of $251,888 and $228,984, respectively

 

 

197,822

 

 

 

210,852

 

Operating right-of-use assets, net

 

 

11,011

 

 

 

12,880

 

Goodwill

 

 

240,681

 

 

 

247,244

 

Other intangible assets, net

 

 

138,074

 

 

 

150,198

 

Deferred income taxes

 

 

15,717

 

 

 

39,809

 

Contract costs, noncurrent portion

 

 

10,249

 

 

 

8,311

 

Other assets

 

 

38,385

 

 

 

39,125

 

Total assets

 

$

1,198,482

 

 

$

1,306,393

 

Liabilities and Shareholders’ Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable – trade

 

$

42,134

 

 

$

60,200

 

Accrued salaries and wages

 

 

38,892

 

 

 

70,552

 

Contract liabilities, current portion

 

 

2,945

 

 

 

39,073

 

Operating lease liabilities, current portion

 

 

4,502

 

 

 

4,305

 

Income taxes payable

 

 

386

 

 

 

19

 

Liabilities held for sale, current portion

 

 

 

 

 

18,086

 

Other current liabilities

 

 

32,076

 

 

 

36,177

 

Total current liabilities

 

 

120,935

 

 

 

228,412

 

Long-term debt, excluding current portion, net of debt issuance costs

 

 

189,421

 

 

 

185,401

 

Deferred income taxes

 

 

6,506

 

 

 

7,381

 

Underfunded pension

 

 

21,786

 

 

 

69,610

 

Contract liabilities, noncurrent portion

 

 

16,528

 

 

 

11,019

 

Operating lease liabilities, noncurrent portion

 

 

7,140

 

 

 

9,325

 

Liabilities held for sale, noncurrent portion

 

 

 

 

 

1,171

 

Other long-term liabilities

 

 

39,837

 

 

 

47,636

 

Commitments and contingencies

 

 

 

 

Shareholders' equity:

 

 

 

 

Preferred stock, $1 par value, 200,000 shares authorized; none outstanding

 

 

 

 

 

 

Common stock, $1 par value, 50,000,000 shares authorized; voting; 30,434,269 and 30,278,668 shares issued, respectively

 

 

30,434

 

 

 

30,279

 

Additional paid-in capital

 

 

248,153

 

 

 

238,829

 

Retained earnings

 

 

750,445

 

 

 

728,764

 

Accumulated other comprehensive income (loss)

 

 

(111,385

)

 

 

(130,821

)

Less 2,573,896 and 2,555,785 shares of common stock, respectively, held in treasury, at cost

 

 

(121,318

)

 

 

(120,613

)

Total shareholders’ equity

 

 

796,329

 

 

 

746,438

 

Total liabilities and shareholders’ equity

 

$

1,198,482

 

 

$

1,306,393

 

KAMAN CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Thousands of U.S. dollars) (unaudited)

 

 

 

Twelve Months Ended

 

 

December 31, 2021

 

December 31, 2020

Cash flows from operating activities:

 

 

 

 

Net earnings (loss)

 

$

43,676

 

 

$

(69,742

)

Less: Total earnings from discontinued operations

 

 

 

 

 

692

 

Earnings (loss) from continuing operations

 

 

43,676

 

 

 

(70,434

)

Adjustments to reconcile net earnings from continuing operations to net cash provided by (used in) operating activities of continuing operations:

 

 

 

 

Depreciation and amortization

 

 

36,654

 

 

 

43,899

 

Amortization of debt issuance costs

 

 

1,836

 

 

 

1,746

 

Accretion of convertible notes discount

 

 

2,957

 

 

 

2,860

 

Provision for doubtful accounts

 

 

575

 

 

 

1,381

 

Impairment on assets held for sale

 

 

 

 

 

36,285

 

Loss (gain) on sale of business

 

 

234

 

 

 

(493

)

Net (gain) loss on sale of assets

 

 

(8

)

 

 

200

 

Goodwill impairment

 

 

 

 

 

50,307

 

Net loss (gain) on derivative instruments

 

 

1,025

 

 

 

(466

)

Stock compensation expense

 

 

6,687

 

 

 

4,979

 

Deferred income taxes

 

 

20,998

 

 

 

(6,055

)

Changes in assets and liabilities, excluding effects of acquisitions/divestitures:

 

 

 

 

Accounts receivable

 

 

78,367

 

 

 

7,042

 

Contract assets

 

 

(3,482

)

 

 

12,629

 

Contract costs

 

 

725

 

 

 

294

 

Inventories

 

 

(10,357

)

 

 

(18,485

)

Income tax refunds receivable

 

 

(8,565

)

 

 

2,763

 

Operating right of use assets

 

 

1,798

 

 

 

1,513

 

Other assets

 

 

3,450

 

 

 

2,490

 

Accounts payable - trade

 

 

(18,398

)

 

 

(9,227

)

Contract liabilities

 

 

(30,708

)

 

 

(29,555

)

Operating lease liabilities

 

 

(1,918

)

 

 

(1,560

)

Acquired retention plan payments

 

 

(25,108

)

 

 

 

Other current liabilities

 

 

(8,880

)

 

 

16,955

 

Income taxes payable

 

 

295

 

 

 

(4,885

)

Pension liabilities

 

 

(37,580

)

 

 

(21,550

)

Other long-term liabilities

 

 

(5,575

)

 

 

(6,164

)

Net cash provided by operating activities of continuing operations

 

 

48,698

 

 

 

16,469

 

Cash flows from investing activities:

 

 

 

 

Proceeds from sale of discontinued operations

 

 

 

 

 

5,223

 

Proceeds from sale of business, net of cash on hand

 

 

(3,428

)

 

 

493

 

Expenditures for property, plant & equipment

 

 

(17,530

)

 

 

(17,783

)

Acquisition of businesses, net of cash acquired

 

 

 

 

 

(304,661

)

Other, net

 

 

(154

)

 

 

(1,994

)

Net cash used in investing activities of continuing operations

 

 

(21,112

)

 

 

(318,722

)

Cash flows from financing activities:

 

 

 

 

Proceeds from exercise of employee stock awards

 

 

2,705

 

 

 

4,296

 

Purchase of treasury shares

 

 

(618

)

 

 

(14,210

)

Dividends paid

 

 

(22,241

)

 

 

(22,210

)

Other, net

 

 

(2,079

)

 

 

(1,411

)

Net cash (used in) provided by financing activities of continuing operations

 

 

(22,233

)

 

 

(33,535

)

Net decrease in cash and cash equivalents

 

 

5,353

 

 

 

(335,788

)

Effect of exchange rate changes on cash and cash equivalents

 

 

(642

)

 

 

337

 

Cash and cash equivalents and restricted cash at beginning of period

 

 

136,089

 

 

 

471,540

 

Cash and cash equivalents and restricted cash at end of period

 

$

140,800

 

 

$

136,089

 

 

Kary Bare

Investor Relations

(860) 243-7485

kary.bare@kaman.com

Source: Kaman Corp.

FAQ

What were Kaman Corp.'s earnings for 2021?

Kaman Corp. reported earnings from continuing operations of $43.7 million for the full year 2021.

How did Kaman Corp.'s net sales perform in Q4 2021?

Kaman Corp. reported net sales of $175.1 million for the fourth quarter of 2021.

What was Kaman Corp.'s gross margin for the year 2021?

Kaman Corp.'s gross margin for 2021 increased to 33.4%.

What are the projected sales for Kaman Corp. in 2022?

Kaman Corp. projects net sales between $720 million and $740 million for 2022.

What was the diluted EPS for Kaman Corp. in 2021?

The diluted earnings per share from continuing operations for Kaman Corp. were $1.57 in 2021.

Kaman Corp

NYSE:KAMN

KAMN Rankings

KAMN Latest News

KAMN Stock Data

1.30B
27.95M
1.26%
89.31%
1.78%
Aerospace & Defense
Guided Missiles & Space Vehicles & Parts
Link
United States of America
BLOOMFIELD